AMI RETA

Price range: R530,00 through R1 730,00

Retatrutide in 15mg, 30mg and 60mg options, each listed as a vial, pen or cartridge. For laboratory research only.

Out of stock

  • Pens and cartridges are made on order.
  • Peptides are received, stored and shipped cold.
Pay byDirect bank transfer

For laboratory research use only. This product is not a medicine and is not for human or veterinary use. It is not intended to diagnose, treat, cure or prevent any disease.

SKU: ARP-retatrutide Categories: ,

Retatrutide is offered in 15mg, 30mg and 60mg options across vial, pen and cartridge formats. It has its own product listing and should not be confused with Tirzepatide or Semaglutide.
A published phase 2 trial describes retatrutide as an agonist at GIP, GLP-1 and glucagon receptors. The trial concerns its investigational material and study conditions, not the Aminos product. No clinical outcome or product approval is claimed here.
Check the compound name as well as the strength when comparing these listings. If your laboratory needs a particular formulation or identity specification, confirm it before placing an order.

Retatrutide, also called LY3437943, is a single peptide agonist of GIP, GLP-1 and glucagon receptors. This triple-receptor profile separates it from tirzepatide and semaglutide.

Identity and context

The three receptor targets describe pharmacology, not three mixed ingredients. A complete retatrutide structure must account for its chemical modifications. This entry deliberately omits a standard-residue-only sequence and calculated molecular mass that would imply an incomplete structure was sufficient.

Reference classification

Modified peptide. The linked catalogue product is Retatrutide. This reference does not independently authenticate the material supplied.